# Eli Lilly

has parlayed its GLP-1 dual-agonist tirzepatide (Mounjaro/Zepbound) into a broader portfolio strategy spanning diabetes, obesity and expanded cardiometabolic indications, reinforcing its position at the January 2026 JPMorgan Healthcare Conference even amid looming patent challenges.

Source: https://en.bioecon.ru/companies/eli-lilly/
Updated: 2026-07-05

- Country: United States
- Ticker: LLY

## Technologies

- [Drug & vaccine development](https://en.bioecon.ru/technology/drug-vaccine-development/)